Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 3Recurrence 3Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Multiple Myeloma 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Lymphoma, T-Cell, Peripheral 1Liposarcoma 1Inhibition of Autophagy Synergizes Anti-tumor Effect 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Genetic Diseases, Inborn 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Gemcitabine 30Mitomycin 25BCG Vaccine 13Docetaxel 10Epirubicin 6erdafitinib 5durvalumab 5dodecyl maltoside 5Radiotherapy 5Cystoscopy 5apaziquone 4ALT-803 4tislelizumab 35-aminolevulinic acid hexyl ester 3viscum album peptide 2pembrolizumab 2disitamab vedotin 2avelumab 2VB4-845 2Therapeutics 2Imiquimod 2Hyaluronic Acid 2Administration, Intravesical 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × Clinical Trials, Phase II as Topic × Clear all
NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

Phase 1/2 Recruiting
350 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡